180 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 … the resource intensive, late stage istaroxime program advanced by a larger company, by adding the innovative aPKCi inhibitor platform to our early
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
3 Apr 07
Discovery Labs to Raise $30 Million in Registered Direct Offering
12:00am
biotechnology company developing its innovative Surfactant Replacement Therapy (SRT) to advance respiratory medicine and address a variety of respiratory … commercialize products that combine Discovery’s drug products with innovative aerosolization technologies, risks relating to drug manufacturing by Discovery
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
9 Jul 04
Other events
12:00am
. With this innovative financing structure now in
place, we have an ability to finance the Company at times when we believe the
appropriate value … parties feel that this process has
resulted in a well thought out and innovative financing vehicle."
Discovery will be hosting a conference call
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
18 Apr 16
Amendments to Articles of Incorporation or Bylaws
12:00am
management team focused on rigorous clinical execution and effective cash management High Value-Creating Potential Innovative synthetic KL4 surfactant … instillate) for RDS approved by the FDA Lyophilized (freeze-dried) KL4 surfactant – developed initially for AEROSURF® Innovative Aerosol Delivery Technology
8-K
EX-99.2
WINT
Windtree Therapeutics Inc
4 Jan 13
Discovery Labs Announces Changes to Board of Directors and Appoints a New Chief Executive Officer
12:00am
Labs’ innovative spirit and progress toward advancing new standards in respiratory critical care.”
The AFECTAIR technology was developed as a component
8-K
EX-99.1
78g4hds28
12 Dec 07
Discovery Labs Announces Completion of $25 Million Registered Direct Offering
12:00am
8-K
EX-99.1
up8qp
2 May 08
Discovery Labs Receives an Approvable Letter from FDA
12:00am
8-K
EX-99.1
fr9dbb2mps
30 Apr 19
Windtree Therapeutics Appoints Daniel Geffken to Board of Directors
4:26pm
8-K
EX-99.1
9b5h2f4h571
9 Dec 19
Windtree Therapeutics Completes $26.4 Million Private Placement
5:09pm
8-K
EX-99.1
xkh5q90e neuecyl
20 Dec 05
Discovery Labs Announces Completion of $20.0 Million Registered Direct Offering
12:00am
8-K
EX-99.1
f8w v7x636w
7 Dec 07
Discovery Labs to Raise $25 Million in Registered Direct Offering
12:00am
8-K
EX-99.3
m4va3w6 3oibi5l
4 Nov 04
Entry into a Material Definitive Agreement
12:00am
8-K
r52jmf s6aufz2mz2cat
28 Jun 12
Entry into a Material Definitive Agreement
12:00am
8-K/A
uyeou01e 1xe
29 Jun 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
0id5qthlo3qzfmpgppmy
26 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
xn13a4a7kf
22 Jun 06
Discovery Labs Retains Jefferies & Company to Assist in the Evaluation of Potential Strategic Alternatives
12:00am
8-K
EX-99.1
aij4 ek57ir
9 Apr 07
Discovery Labs Announces Completion of $30 Million Registered Direct Offering
12:00am
8-K
EX-99.1
pi10yjrf
14 Dec 05
Discovery Labs to Raise $20.0 Million in Registered Direct Offering
12:00am
8-K
EX-99.2
kshnfny55yzshyqf
10 Nov 08
Discovery Labs Reports Third Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
ym5c9471w7xn68t ob
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm